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smOoth muscle celia (SMC), SM-20 mRNA was found at low levels in qui- 
escent SMC and induced within 30 min by growth agonists and vasoactive 
agents. SM-20 mRNA was present in smooth, skeletal, and cardiac muscle 
as well as brain but not in other non-muscle tissues. We now report he iden- 
tification and characterization of SM-20 protein, An affinity purified polycional 
antibody was raised against a bactedally expressed 230 amino acid portion 
of the 5M-20 open reading frame. Western blot analysis of smOoth, skele- 
tal, and cardiac music revealed a single major protein species at ~ kD. 
The cDNA arld amino acid sequences were unique from all other mammalian 
sequences currently in the GenBank. ImmunohistocherniStn/revealed that 
SM.2O encodes an intracelluler protein whose expression in the vessel wail is 
specific to the medial SMC of normal adefies and is increased in the intimal 
SMC of ballOon.injured rat aorta and atheroeclerotic human coronary arteries. 
SM,20 antigen is not found in artedal endothelium, adventitial fibroblasts or 
maCrophages. To examine its regulation in sarcornodc tiSsue, SM-20 was as- 
sayed in mouse C20~ myoblasts. In proliferating C,aC~, SM-20 mRNA was 
present at low levels. Following d~erentiatioo by 3% horse serum, there was 
a marked increase in SM-20 rnRNA, Immunostaining failed to detect SM-20 
antigen in proliferating, unfused myoblasts, but revealed intense staining in 
fused myotubes. SM-20 mRNA was not present in BC3H1, a mouse myocyta 
line defective for cell fusion. SM-20 thus eppeam to be a marker for myacyta 
fusion. SM-20 mRNA was present at low levels in fetal rat heart and was 
markedly increased in adult and hypedrephied hearts. Immunostaining identi- 
fied SM-20 antigen at low levels in the heart and semite pairs of 0.5 day mouse 
embryos with a rostral to caudal distribution gradient. SM-20 antigen was de- 
tected in smooth, skeletal muscle and heart at 10.5 days and increased in 
intensity in these tissues throughout the remainder of development. SM-20 is 
a novel protein whose expression is restricted in the vessel wall to SMC. SM- 
20 is also regulated during the development of smooth, skeletal, and cardiac, 
muscle and may play a role in myogenic dilferentiation or cell fusion. 
CORONARYNASCULAR PHYSIOLOGY- CLINICAL 
~ Acute Cholesterol Lowering With LDL-Apheresis 
Irnprove~s Endothelial Function of the Epicarcliai 
Coronary Artery In Patients With 
Hypercholesterolemla 
Keiichi Igarashi, Masashi Hodmoto, Takashi Takenaka, Hitold Inoue, 
Setswa Mlyata. Division of Cardiology, Sapporo National Hospital, 
Sapporo, Japan. 
The endotheilum-depondent vasodllation of the epicardial coronary artery in 
patients with hypemholesterolemia s impaired and restored with the choles- 
te¢ol Iowedng drugs. To examine whether acute cholesterol Iowedng with 
LDL-epherosis (LDL-aDh) improves endothelial function of the epicardial 
coronary artery, we studied in 10 patients (< 25% focal atancsis) the coronary 
diameter response with intracoronary acetylcholine (ACh) as endotheiium 
dependent vasoditafur and isosorbide dinitrate (ISDN) as endothelium inde- 
pendent vasodilator before and alter LDL-aph. After LDL-aph LDL cholesterol 
decreased by 98 ± 5% from 231 :~ 16 rag/all (p < 0.001). Mean blood pres- 
sure and heart rate didn't change with LDL-eph. ACh and ISDN responses 
were assessed in the same proximal LAD segment by quantitative coronary 
angiography as % internal diameter change (A% ID). 
ACh 10 -7 M ACh 10 -6 M ISDN 2.5 mg 
zs% ID pm LDL-aph. -0.2 4. 3.0 -20.1 4- 6.2 15.5 4. 4.9 
/1% ID post. 8.2 ± 2.g* -1.0 -I- 1.6" 8.3 :k 2.6 
M~an 4. SEM, *< 0.02 vs. pre LDL-aph. 
Conclusion: Endothelial function of the epicardial coronary artery in pa- 
ti0nts with hypemholesterelemia can be improved by acute cholesterol low- 
ering, Thls finding suggests that LDL cholesterol directly impairs endothelial 
function of the epicardlal coronary artery. 
~ Angiotens in  Converting Enzyme Inhibition, W'dh 
Quinapri l ,  Improves Endothelial Vasomotor  
Dysfunction in Patients With Coronary Artery 
Disease: The TREND Study (Trial on Reversing 
ENdothel ial  DysfUnction) 
G.B. John Mancini, Gregory C. Henry, Michael I. Klibaner, Thomas 
J. Wargovlch, Bertram Pitt, on behalf of the TREND investigators. University 
of British Columbia, Vancouver, Canada 
Ouinapril (Q) is a potent antagonist of tissue ACE that prevents local synthe- 
sis of angiotansin II and degradation of bradykinin which stimulates endothe- 
lial nitric oxide production. Acute infusion of Q into the forearm of humans 
decreases forearm vascular resistance and increases blood flow. To deter- 
mine if O can improve coronary endothelial dysfunction, patients undergoing 
PTCA with an adjacent _< 40% coronary stenoses (median 22.6%) exhibiting 
vasoconstriction or lack of vesedilaifun to acatylcholine (ACH) as analyzed 
by quantitative coronary angiugraphy were randomized to Q 40 mg dally or 
placebo for 6 months. The primary endpoint was the mean % change in ACH- 
induced diameter of the target segment. Net improvements are presented 
below: 
ACH Q (N = 51) P (N = 54) P-Value 
10 rs M 4..5 ± 3.0% -0.1 4- 2.P/, 
10 -.4 M 12.1 4-3.0=/° -0-8"4" P-8% 0,0~ 
Thus, Q improves endothelial dysfunction, ---'~ e~y m-.~Tker o| ce~onary 
atheresclerosis, in mildly diseased coronary arteries, Which may have impor- 
tant implications for the therapy of ischemic heart disease. 
~"9"01--'~ Normallzaffon ofCoronary Row Reserve 
tmmedlately Alter Stenting but Not After PTCA 
Terry R, Bowers, Robert D. Safian, Richard E. Stewart, Mazan M. Shoukfeh, 
Keith H. Benzuly, William W. O'Neill. William Beaumont HoSpital, Royal 
Oak, MI 
Coronary Row Reserve (CFR) assessment has been unreliable after coro- 
nary interventions. Although successful PTCA may not result in normalization 
of Doppler CFR, the impact of stenting on CFR is unknown. Accordingly, basal 
average peak ¢eioclty (APV) and CFR (hyperemic APV/bacal APV, assessed 
after IC Adenosine; 10 meg RCA, 20 mcg LAD) were measured distal to the 
stanosis with the Doppler Rewire in 17 patients (8 RCA, 9 LAD) at base- 
line, after PTCA, and after elective Paimaz-Schaiz stsnting. Patients with 
leR vantricular dysfunclJon, hypertrophy, or pdor myocardial infarction were 
excluded. Blood pressure and heart rate did not differ between baseline and 
pest-stoat measurements. CFR normalized in all 17 patients when assessed 
5--20 minutes after stent deployment (Final CFR 2.1--4.5). 
Baseline PO~t-PTCA Pob'1-Stent p(ANOVA) 
Basal APV (ccNsec) 19.2 4- 2.0 26.8 4- 3.3 23.S + 2.6 NS 
Hypor APV (crNsec) 22.44.2.4 45.5=1:?.4 61.5+6.1 ,0.0001 
CFR 1.18-;-0.07 t.784.0.23 2.~-;- 0.1P <0.0001 
CFR > 2.0 (%) 0 2 (17) 17 (100}" <0.0001 
Diameter S~n (%) 76.,3-2 324-3 -5±2* <0.0001 
Mean :k SEM; ~p ~ 0.01 Post-Stent vs PoSt-PTCA 
Conc,',Js/ons: In contrast to PTCA, stenting results in normalization of 
coronary flow reserve, probably due to better lumen enlargement, elimination 
of dissection, and improvement in laminar flow. These data suggest that 
failure to nermaiiz~ CFR after PTCA is due to angiogrephically-inapparent 
disturbances in flow, not microvascular disease. 
DEFIBRILLATION/IMPLANTABLE ANTIARRHYTHMIA 
DEVICES 
~ Phenylephrlne Increases Vselricular Rbf l l lat ion 
Threshold in Humane Independent of  the 
Berorsflex Sensitivity 
Raul D. Mitrani, William M. Miles, Lawrence S. Klein, Douglas P. Zipes. 
Indiana University Me,cat Center. Krannert Institute of C, ar~ck2#g 
Indianapolis, IN 
Vegal stimulation has been shown to increase ven~cular f~rillation (VF) 
threshold (1") in animal studies. Furthermore, enhanced bamroflex sensitivity 
(BRS) has been associated with decreased sk fur sudden cardiac death. To 
determine whether egal stimulation inmeases VFT in humans and whether 
the change in VFT is related to BRS, we induced VF twice in 19 patients 
(pts) with implantable cardiover tar-dale, dilators during phenylephdne infusion 
randomized either before the 1at or 2rid VF induction in a dose titrated to 
increase systolic blood pressure (BP) by >20 mm Hg. T wave shocks coupled 
at 310 ms after 8 ventdcular paced complexes at 400 ms were delivered using 
increasing energy until VF was induced. Phenytephdne did not change (n = 
8 patients) or increased (n = 11 patients) the energy required to induce VF. 
Dudng phenylephdse infusion, the mean energy increased from 0.98 joules 
to 1.55 joule6 (p ~- 0.035} -./nile inore~ing mean artedal BP from 86 to 114 
mrn Hg (p < 0.001) and decreasing heart rate from 71 to 57 beats per mint,to 
(p < 0.001). The BRS (A sinus cycle langth/A mean BP) varied from -13 
to +54 ms/ram Hg and was not related I0 the A energy required to induce 
VR The was no change in the interval from the onset of vehicular pacing 
to the peak of the T-wave dudng phenylephdne infusion compared with no 
phenylephrLte infusion (Sl-peak T wave: 306 vs. 308 ms; p = NS. 
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